Trial reportPediatric nephrology (Berlin, Germany)2004
Enalapril in children with Alport syndrome.
Trial report in Pediatric nephrology (Berlin, Germany), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 80 citations in OpenAlex.
- Cyclosporine A treatment in patients with Alport syndrome: a single-center experience.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Cyclosporin therapy in patients with Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2006Trial
- Identification of 27 Novel Variants in GenesFrontiers in medicine · 2022Article
- HMGB-1 and TGFβ-1 highlight immuno-inflammatory and fibrotic processes before proteinuria onset in pediatric patients with Alport syndrome.Journal of nephrology · 2021Article
- A child with familial glomerulonephritis: Answers.Pediatric nephrology (Berlin, Germany) · 2020Article
- Article
- Basement Membrane Defects in Genetic Kidney Diseases.Frontiers in pediatrics · 2018Review
- Alport's syndrome with type 4 renal tubular acidosis.BMJ case reports · 2017Article
- Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy.Pediatric nephrology (Berlin, Germany) · 2016Article
- Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2016Article
- Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.Pediatric nephrology (Berlin, Germany) · 2013Article
- Glomerular pathology in Alport syndrome: a molecular perspective.Pediatric nephrology (Berlin, Germany) · 2012Review
- Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients.ISRN pediatrics · 2012Article
- Article
- Alport Syndrome: De Novo Mutation in the COL4A5 Gene Converting Glycine 1205 to Valine.Clinical medicine insights. Pediatrics · 2012Article
- Ventricular septal defect in a child with Alport syndrome: a case report.BMC cardiovascular disorders · 2010Article
- Diagnosis of Alport syndrome without biopsy?Pediatric nephrology (Berlin, Germany) · 2007Article
- The effect of aldosterone blockade in patients with Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2006Article
- Ontogeny of drug elimination by the human kidney.Pediatric nephrology (Berlin, Germany) · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ten pediatric patients with Alport syndrome received enalapril for 5 years. There were nine boys. Eight patients have the X-linked form of the disease and two the autosomal recessive form. The median age at the start of treatment was 10.25 years. Only one patient was hypertensive. The starting dose of enalapril was 0.05 mg/kg; the target dose was 0.5 mg/kg per day. The median dose given effectively was 0.24, 0.37, 0.45, 0.43, and 0.49 mg/kg per day at years of study 1, 2, 3, 4, and 5, respectively. The median urinary protein/creatinine ratio was 1.58 g/g (range 0.49-4.60) before treatment. This decreased to 0.98, 1.09, 1.35, 1.11, and 1.38 g/g after 1, 2, 3, 4, and 5 years, respectively. The median creatinine clearance at baseline was 100 ml/min per 1.73 m2 (range 82-133) and after 5 years 92 ml/min per 1.73 m2 (range 22-115). Three patients did not reach the target dose of enalapril because of orthostatic hypotension. One of them was the only patient to develop chronic renal failure within 5 years. The present study indicates that enalapril reduces urinary protein excretion and preserves glomerular filtration in Alport patients as a group. However, there was individual variation, as in most studies of patients with proteinuric nephropathies given inhibitors of the angiotensin-converting enzyme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.